CRISPR Therapeutics AG is a biotechnology company developing gene-based medicines for serious diseases through its CRISPR/Cas9 gene-editing platform. Its work includes ex vivo therapies, in which a patient’s cells are edited outside the body before reinfusion, and in vivo approaches designed to modify genetic targets directly within the body. The company’s current portfolio spans blood disorders, oncology, autoimmune diseases, cardiovascular conditions, and type 1 diabetes. Its leading therapy, CASGEVY, is a gene-edited cell therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that edits blood-forming stem cells to support production of fetal hemoglobin. CRISPR Therapeutics AG also develops allogeneic CAR T-cell programs intended to address cancer and autoimmune indications, alongside gene-editing candidates targeting cardiovascular risk factors and stem-cell-derived therapies for diabetes. Headquartered in Zug, Switzerland, the company operates at the intersection of biotechnology, cell therapy, and precision medicine, contributing to the development of treatments that address disease at the genetic or cellular level.
www.crisprtx.com